



Zika Virus: An Update-A Brief Review

M Jaivant¹, MS Nandini^{2*}, S Hariharan³ and B Krishna Prasanth⁴

^{1,3,4}*Department of Community Medicine, Bharath Institute of Higher Education and Research,
Chennai, Tamil Nadu, India*

²*Department of Microbiology, Bharath Institute of Higher Education and Research, Chennai,
Tamil Nadu, India*

**Corresponding e-mail: drmsnandini@gmail.com*

Received: 24-May-2021, Manuscript No. IJMRHS-21-32124; **Editor assigned:** 27-May-2021,
Pre QC No. IJMRHS-21-32124 (PQ); **Reviewed:** 10-June-2021, QC No. IJMRHS-21-32124;
Revised: 10-February-2023, Manuscript No. IJMRHS-21-32124 (R); **Published:** 10-
March-2023.

ABSTRACT

Zika virus is a mosquito borne disease caused by the Flavivirus genus and the Flaviviridae family of arthropod borne viruses (arbovirus). The Zika virus is predominantly transmitted by Aedes aegypti, but the virus can also be transmitted by other Aedes species. In Africa, ZIKV was first isolated from rhesus monkeys in 1947 and from mosquitoes in 1948. For half a century before appearing in the Pacific and the Americas, ZIKV infections in humans were intermittent. ZIKV is normally spread via the bite of mosquitoes that are infected. The clinical presentation of Zika fever, especially those due to arboviruses such as dengue and chikungunya, is unspecific and may be misdiagnosed as other infectious diseases. Before the major french diagnosis, the virus gained the attention of public health authorities because of its strongly suspected relationship with maternal fetal transmission and microcephalus in infected animals. ZIKV infection was only associated with mild disease. Serological diagnosis is complicated by cross reactivity among members of the genus Flavivirus. Moreover, this article will give a brief review on Zika virus epidemic in India.

Keywords: *Zika virus, Mosquito borne disease, Flavivirus, Infection*

INTRODUCTION

The *Zika virus* is now a global epidemic. Evidence of Zika transmission has been recorded in more than 72 countries and territories since 2007. The transfer of ZIKA has prompted the World Health Organization (WHO) to recognize the situation as a health emergency. This situation is critical because the link between infection during pregnancy and the incidence of microcephaly and Guillain Barre syndrome appears to be highly tangible. The *Zika virus* is an icosahedral, enveloped, single stranded RNA virus. A virus spread mainly by *Aedes* mosquitoes causes the *Zika virus* disease. In February 2016, the WHO declared the *Zika virus* and its related complications a public health emergency of the international concern. In the United States, *Zika virus* infection is among the globally notifiable diseases. An unexplained sharp rise in the occurrence of babies born with microcephaly and a summary of a new disease, congenital Zika syndrome, followed the first outbreak of infection with the *Zika virus* in Brazil [1].

approximately 10,000 blood and throat swab samples were screened as part of the surveillance programme of US Naval Medical Research Unit [3].

The global prevalence of *Zika virus* infection has not been widely reported owing to asymptomatic clinical course, clinical resemblance to other infection with other *Flaviviruses* (dengue, chikungunya), and difficulty in confirming diagnosis. Based on sporadic case reports, entomological surveys and seroprevalence surveys, *Zika virus* infection had been reported in various hosts, including humans, primates, and mosquitoes, in 14 countries across Africa, Asia, and Oceania, as of 2014. *Zika* viral infection has been registered in more than 28 countries with the highest number of infections in Brazil in 2016. The latest outbreak in Brazil began in the month of April, in the year 2015. The town of 'Natal,' located in the state of Rio Grande do Norte in the northeast of Brazil, registered the first case of infection with ZIKV. Shortly afterward, virus spread throughout the country and frequent reports of microcephaly coincided with ZIKV infections [4].

Transmission

Zika virus is transmitted to humans mainly through the bite of infected *Aedes* mosquito species (*Ae. aegypti* and *Ae. albopictus*). These are the same mosquitoes which spread dengue and chikungunya viruses. A pregnant woman can transfer *Zika virus* to her fetus during pregnancy. *Zika* is a cause of microcephaly and other significant fetal abnormalities of the brain. We're researching the full range of other potential health problems that *Zika virus* infection can cause during pregnancy. A pregnant woman who has already been infected with *Zika virus* will transmit the virus to her fetus during pregnancy or around the time of birth. *Zika virus* has been discovered in breast milk. Possible infections of the *Zika virus* in breast feeding infants have been reported, but transmission of the *Zika virus* via breast milk has not been confirmed [5]. In addition, we do not yet know the long term effects of *Zika virus* on young infants that have been infected after birth. Since existing research shows that the benefits of breastfeeding outweigh the risk of *Zika virus* transmission by breast milk, CDC tends to encourage mothers to breastfeed, even though they have been infected or lived in or travelled to areas at risk of *Zika*. *Aedes aegypti* and *Aedes albopictus* were recognized as major vectors for transmission of *Zika virus*. Since then, the infection has spread rapidly to several other countries, becoming a pandemic. The main mode of transmission is through the bite of an infected mosquito, although few sexual transmission events have been reported. The risk of infection depends therefore on the local risk of mosquito borne transmission. It may be high during epidemics, but lower levels of ongoing virus circulation are still expected in areas where ZIKV circulation is considered endemic; in these areas the risk of is low to medium [6-8]. Sexual transmission among humans has also been described. In addition, great concern is emerging over congenital malformations due to trans placental transmission of *Zika virus*, including microcephaly and various ophthalmic abnormalities. *Zika* can be passed through gender from a person who has *Zika* to his or her partners. *Zika* can be passed through gender, even if the infected person does not have symptoms at the time. There have been several accounts of potential cases of blood transfusion in Brazil. During the French Polynesian outbreak, 2.8% of blood donors tested positive for *Zika* and in previous outbreaks, the virus was detected in blood donors [9-11].

Pathophysiology

Zika virus is well adapted to grow in various hosts, ranging from arthropods to vertebrates. Viral attachment to unidentified cellular receptors is mediated by the E (Envelope) glycoprotein. This is followed by endocytic uptake and then uncoating of the nucleocapsid and release of viral RNA into the cytoplasm [12-14]. A viral polyprotein is produced and modified by the endoplasmic reticulum. Immature virions collect both in the endoplasmic reticulum and in secretory vesicles before being released [15].

Clinical symptoms

Zika is usually mild with symptoms lasting from days to weeks. People usually don't get sick enough to go to the hospital and very rarely die of *Zika*. For this reason, many people may not realize that they have been infected. Symptoms of *Zika* are similar to other viruses transmitted by mosquito bites, such as dengue and chikungunya. *Zika virus* typically stays in the blood of an infected person for around a week. If you develop symptoms and live in or have recently travelled to a *Zika* risk location, see your doctor or other health care provider. Your doctor or other

health care provider can order a blood or urine test to help decide if you have Zika. If a person is infected, he or she is likely to be safe from potential infections [16-18].

The spectrum of *Zika virus* disease overlaps with that of arboviral infections, but rash (maculopapular and potentially immune mediated) is usually predominant. Rash in *Zika virus* infection is typically a fine maculopapular rash that is diffusely dispersed. It can include the face, trunk, and extremities, including palms and soles. Occasionally, the rash may be pruritic. Rash, along with other symptoms, typically develops within 2 weeks of travel to the infected region of the *Zika virus*. *Zika virus* rash typically develops in the first week of infection, with infection itself lasting from days to weeks. *Zika virus* infection should therefore be regarded among individuals with acute myelitis who reside in or travel from endemic areas of *Zika virus* [19].

Laboratory investigations

Zika virus infection is diagnosed based on the identification and isolation of *Zika virus* RNA from serum using Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). During the initial week of illness, the greatest sensitivity of PCR testing is marked by high viremia. Serological tests for virus-specific Immunoglobulin M (IgM) and anti-*Zika virus* neutralising antibodies can be performed after the initial week of illness using the Enzyme Linked Immunosorbent Assay (ELISA). Diagnosis of *Zika virus* infection is generally focused on serological tests, but the CDC is now recommending the tests of urine. Urine can be tested using real time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) samples obtained less than 2 weeks after onset of symptoms [20].

Treatment

There are no specific treatment options for *Zika virus* infection.

Prevention and control

There is no vaccine for *Zika virus*. The best way to prevent infection with *Zika virus* is to avoid travel to areas with active transmission of *Zika virus*. Residents living in endemic areas or visitors to endemic areas are recommended to prevent mosquito bites.

CONCLUSION

Various methods to avoid mosquito bites include wearing full sleeved shirts and long pants, sleeping under a mosquito bed sheet, and clothing treatment with permethrin. Mosquito repelling agents such as DEET, picaridin, IR3535, and para-menthane-diol can be used in all age groups except those younger than 2 months for the prevention of mosquito bites. Mosquito larval habitats can be managed by the careful handling of water containers, including routine discarding or covering stagnant water or by the use of larvicidal agents.

REFERENCES

- [1] Faye O, et al. Molecular evolution of *Zika virus* during its emergence in the 20th century. *PLOS Negl Trop Dis*, Vol. 8, No. 1, 2015, pp. 26-36.
- [2] Dick GW, Kitchen SF, Haddock AJ. *Zika virus* (I). Isolations and serological specificity. *Trans R Soc Trop Med Hyg*, Vol. 46, No. 5, 2014, pp. 509-520.
- [3] Bogoch II, et al. Anticipating the international spread of *Zika virus* from Brazil. *Lancet*, Vol. 387, No. 10016, 2016, pp. 335-336.
- [4] Gatherer D and Kohl A. *Zika virus*: A previously slow pandemic spreads rapidly through the Americas. *J Gen Virol*, Vol. 97, No. 2, 2016, pp.269-273.
- [5] Kelser EA. Meet dengue's cousin, Zika. *Microbes Infect*, Vol. 18, No. 3, 2015, pp. 163-166.
- [6] Attar N. *Zika virus* circulates in new regions. *Nat Rev Microbiol*, Vol. 14, No. 2, 2016, pp. 62.
- [7] Dick GW, Kitchen SF and Haddock AJ. *Zika virus* (II): Pathogenicity and physical properties. *Trans R Soc Trop Med Hyg*, Vol. 46, No. 5, 1952, pp. 17-19.
- [8] Heang V, et al. *Zika virus* infection, Cambodia, 2010. *Emerg Infect Dis*, Vol. 18. No. 2, 2012, pp. 349.

-
- [9] Henderson BE, Hewitt LE and Lule M. Serology of wild mammals. *Annu Rev Virol*, Vol. 3. No. 4, 1968, pp. 48-51.
- [10] Driggers RW, et al. *Zika virus* infection with prolonged maternal viremia and fetal brain abnormalities. *N Engl J Med*, Vol. 374, No. 22, 2016, pp. 2142-2151.
- [11] Musso D, et al. Potential sexual transmission of *Zika virus*. *Emerg Infect Dis*, Vol. 21, No. 2, 2015, pp. 359.
- [12] Hills SL. Transmission of *Zika virus* through sexual contact with travelers to areas of ongoing transmission continental United States, 2016. *Morb Mortal Wkly Rep*, Vol. 5, No. 4, 2016, pp. 65.
- [13] Meaney Delman D, et al. Prolonged detection of *Zika virus* RNA in pregnant women. *Obstet Gynecol*, Vol. 128, No. 4, 2016, pp. 724-730.
- [14] Musso D, et al. Potential for *Zika virus* transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. *Eurosurveillance*. Vol. 19, No. 14, 2014, pp. 20761.
- [15] Tamura K, et al. MEGA6: Molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol*, Vol. 30, No. 12, 2013, pp. 2725-2729.
- [16] Dick GW, Kitchen SF and Haddow AJ. *Zika virus* (I). Isolations and serological specificity. *Trans R Soc Trop Med Hyg*, Vol. 46, No. 5, 1952, pp. 509-520.
- [17] Marchette NJ, Garcia R and Rudnick A. Isolation of *Zika virus* from *Aedes aegypti* mosquitoes in Malaysia. *Am J Trop Med*, Vol. 18, No. 3, 1969, pp. 24-26.
- [18] Weinbren MP and Williams MC. *Zika virus*: Further isolations in the Zika area, and some studies on the strains isolated. *Trans R Soc Trop Med Hyg*, Vol. 52, No. 3, 1958, pp. 263-268.
- [19] Olson JG and Ksiazek TG. *Zika virus*, a cause of fever in Central Java, Indonesia. *Trans R Soc Trop Med Hyg*, Vol. 75, No. 3, 1981, pp. 389-393.
- [20] Vanya M. Prevention of *Zika virus* and related complications. *Rev Med Microbiol*, Vol. 28, No. 2, 2017, pp. 75-78.